Opko Health Inc.  

(Public, NASDAQ:OPK)   Watch this stock  
Find more results for NYSE:OPK
+0.09 (0.91%)
Real-time:   1:18PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.07 - 9.46
52 week 9.07 - 9.46
Open 9.12
Vol / Avg. 1.88M/3.84M
Mkt cap 5.16B
P/E 67.34
Div/yield     -
EPS 0.14
Shares 547.44M
Beta 1.41
Inst. own 20%
Aug 3, 2016
Q2 2016 OPKO Health Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 17, 2016
OPKO Health Inc Annual Shareholders Meeting (Estimated)
Jun 15, 2016
OPKO Health Inc Analyst & Investor Day
Jun 9, 2016
OPKO Health Inc at Jefferies Healthcare Conference
May 9, 2016
Q1 2016 OPKO Health Inc Earnings Call
May 9, 2016
Q1 2016 OPKO Health Inc Earnings Release
May 5, 2016
OPKO Health Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -3.31% -4.95%
Operating margin -9.46% -20.03%
EBITD margin - -11.44%
Return on average assets -1.38% -1.20%
Return on average equity -2.42% -2.13%
Employees 5,936 -
CDP Score - -


4400 Biscayne Blvd
MIAMI, FL 33137-3212
United States - Map
+1-305-5754138 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company's diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.

Officers and directors

Phillip Frost M.D. Chairman of the Board, Chief Executive Officer
Age: 79
Bio & Compensation  - Reuters
Jane H. Hsiao Ph.D. Vice Chairman of the Board, Chief Technical Officer
Age: 67
Bio & Compensation  - Reuters
Adam E. Logal Chief Financial Officer, Senior Vice President
Age: 37
Bio & Compensation  - Reuters
Steven D. Rubin Esq. Executive Vice President - Administration, Director
Age: 55
Bio & Compensation  - Reuters
Thomas E. Beier Director
Age: 69
Bio & Compensation  - Reuters
Robert A. Baron Independent Director
Age: 75
Bio & Compensation  - Reuters
Dmitry Yurevich Kolosov Independent Director
Age: 36
Bio & Compensation  - Reuters
Richard Alan Lerner M.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
John A. Paganelli Independent Director
Age: 80
Bio & Compensation  - Reuters